Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Impel Pharmaceuticals, Inc.

Tonix Pharmaceuticals Holding Corp.

Aytu Biopharma, Inc.

Biofrontera, Inc.

RenovoRx, Inc.

Iterum Therapeutics Plc

Cingulate, Inc.

Eterna Therapeutics, Inc.

Lipella Pharmaceuticals, Inc.

GT Biopharma, Inc.

Lucy Scientific Discovery, Inc.

Why is Tonix Pharmaceuticals Holding Corp. ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Negative results in Jun 25

NET SALES(Q) Lowest at USD 2 MM
OPERATING PROFIT(Q) Lowest at USD -27.81 MM
OPERATING PROFIT MARGIN(Q) Lowest at -1,392.04 %

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -26.67%, its profits have risen by 33.7%

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -26.67% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Tonix Pharmaceuticals Holding Corp. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Tonix Pharmaceuticals Holding Corp.

5.57%

-0.01

9789.49%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

61.04%

EBIT Growth (5y)

-169.46%

EBIT to Interest (avg)

-91.98

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.73

Sales to Capital Employed (avg)

0.09

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

9.53%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.65

EV to EBIT

-2.29

EV to EBITDA

-2.38

EV to Capital Employed

3.40

EV to Sales

16.56

PEG Ratio

Dividend Yield

ROCE (Latest)

-148.11%

ROE (Latest)

-38.82%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -66.9 MM

NET PROFIT(HY)

Higher at USD -43.01 MM

RAW MATERIAL COST(Y)

Fallen by -17.7% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -74.31 %

-16What is not working for the Company

NET SALES(Q)

Lowest at USD 2 MM

OPERATING PROFIT(Q)

Lowest at USD -27.81 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -1,392.04 %

PRE-TAX PROFIT(Q)

Lowest at USD -28.27 MM

NET PROFIT(Q)

Lowest at USD -28.27 MM

Here's what is working for Tonix Pharmaceuticals Holding Corp.

Operating Cash Flow

Highest at USD -66.9 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Debt-Equity Ratio

Lowest at -74.31 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -17.7% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Tonix Pharmaceuticals Holding Corp.

Net Sales

At USD 2 MM has Fallen at -20.41%

over average net sales of the previous four periods of USD 2.51 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -28.27 MM has Fallen at -61.5%

over average net sales of the previous four periods of USD -17.51 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -28.27 MM has Fallen at -61.5%

over average net sales of the previous four periods of USD -17.51 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Net Sales

Lowest at USD 2 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Operating Profit

Lowest at USD -27.81 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin

Lowest at -1,392.04 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at USD -28.27 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -28.27 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)